Seroquel | Quetiapine Tablet while Breastfeeding

It is recommended to breastfeed exclusively for six months and then while introducing to other food sources extend it to twelve months. In this duration most mothers will need help of some sort of medication, It could be for short term like could and flue or it could be something chronic like Arthritis or Diabetes and here comes the question of safety of medication in use. In this post we will figure out what is Seroquel | Quetiapine Tablet and whether its safe to use Seroquel | Quetiapine Tablet while nursing or not.

SEROQUEL is an atypical antipsychotic indicated for the: Treatment of schizophrenia (1.1) •Adults: Efficacy was established in three 6–week clinical trials in patients with schizophrenia (14.1) •Adolescents (ages 13–17): Efficacy was established in one 6–week trial in patients with schizophrenia (14.1) Acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex (1.2) •Adults: Efficacy was established in two 12–week monotherapy trials and in one 3–week adjunctive trial in patients with manic episodes associated with bipolar I disorder (14.2) •Children and Adolescents (ages 10–17): Efficacy was established in one 3–week monotherapy trial in patients with manic episodes associated with bipolar I disorder (14.2) Acute treatment of depressive episodes associated with bipolar disorder (1.2) •Adults: Efficacy was established in two 8–week trials in patients with bipolar I or II disorder (14.2) Maintenance treatment of bipolar I disorder as an adjunct to lithium or divalproex (1.2) •Adults: Efficacy was established in two maintenance trials in adults (14.2) 1.1 Schizophrenia SEROQUEL is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL in schizophrenia was established in three 6-week trials in adults and one 6–week trial in adolescents (13–17 years). The effectiveness of SEROQUEL for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.1)]. 1.2 Bipolar Disorder SEROQUEL is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10-17 years) [see Clinical Studies (14.2) ]. SEROQUEL is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [see Clinical Studies (14.2) ]. SEROQUEL is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of SEROQUEL as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.2) ]. 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers SEROQUEL was excreted into human milk. It is recommended that women receiving SEROQUEL should not breast feed. In published case reports, the level of quetiapine in breast milk ranged from undetectable to 170 μg/L. The estimated infant dose ranged from 0.09% to 0.43% of the weight-adjusted maternal dose. Based on a limited number (N=8) of mother/infant pairs, calculated infant daily doses range from less than 0.01 mg/kg (at a maternal daily dose up to 100 mg quetiapine) to 0.1 mg/kg (at a maternal daily dose of 400 mg).